journal article·2024-04-26

Degradable Mesoporous Silica Nanoparticle/Peptide-Based “Trojan Horse”-like Drug Delivery System for Deep Intratumoral Penetration and Cancer Therapy

Tao Liao, Chang Liu, Xiaomei Wu, Jia Liu, Wenqian Yu, Ziqiang Xu, Ying Kuang, Cao Li

ACS Applied Nano Materials· Volume 7· Issue 8
Publisher page

Abstract

For conventional anticancer drug delivery systems (DDSs), it is difficult to endow them with both long circulation in vivo and easy cellular endocytosis by cancer cells as well as the ability to accumulate in tumors through the enhanced permeability and retention (EPR) effect and deep intratumoral penetration. Therefore, their in vivo treatment effects are inadequate. Previous studies have shown that “dynamic protection” strategies can effectively address the difficulty of DDS entry into cancer cells as a result of modifying “stealthy” molecules such as poly(ethylene glycol) (PEG). In this work, a “Trojan horse”-like DDS was fabricated by employing the “dynamic protection” strategy. The DDS was developed using ultrasmall, degradable mesoporous silica nanoparticles (DS-MSN) that were bridged by a degradable peptide and cross-linked with 4-arm PEG-N 3 through click chemistry. This resulted in DOX-DS-MSN-CD-peptide-PEG with a size of ∼300 nm, which could accumulate in the tumor, following adequate blood circulation. The peptide could be degraded by matrix metalloproteinase-2 (MMP-2), an overexpressed enzyme in tumors, leading to the release of small-sized, tumor-permeable DS-MSN-based carriers. The remaining Arg-Gly-Asp (RGD) peptide on the surface provides the carriers with a “tumor-triggered targeting” capability. DS-MSN, which includes disulfide bonds in its backbone, could be degraded due to glutathione (GSH) in cancer cells and release of the loaded doxorubicin hydrochloride (DOX). In vitro and in vivo experiments showed that DOX-DS-MSN-CD-peptide-PEG had a prolonged circulation time and tumor accumulation ability, excellent tumor penetration ability, and controlled drug release ability. It operated like a “Trojan horse”, overcoming obstacles to deliver the “Greek soldier” DOX to the interior of cancer cells, resulting in effective tumor suppression. This study offers interesting concepts for designing effective and safe drug delivery systems.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Hubei Key Laboratory of Industry Microbiology, National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan 430068, China

Ministry-of-Education Key Laboratory for the Green Preparation and Application of Functional Materials, Hubei Key Laboratory of Polymer Materials, Hubei University, Wuhan 430062, China

Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, College of Health Science and Engineering, Hubei University, Wuhan 430062, China

Funding

National Natural Science Foundation of China

References (42)

Show source-provided references
1. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
2. 10.1038/s41568-022-00496-910.1038/s41568-022-00496-9 ↗
3. 10.1007/s11426-022-1271-010.1007/s11426-022-1271-0 ↗
4. 10.1002/adma.20220952910.1002/adma.202209529 ↗
5. 10.1002/adma.20140155410.1002/adma.201401554 ↗
6. 10.1002/adma.20160662810.1002/adma.201606628 ↗
7. 10.1021/acs.chemrev.3c0006210.1021/acs.chemrev.3c00062 ↗
8. 10.1039/D0CS01127D10.1039/D0CS01127D ↗
9. 10.1038/s41392-022-00947-710.1038/s41392-022-00947-7 ↗
10. 10.1016/j.addr.2023.11504410.1016/j.addr.2023.115044 ↗
11. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
12. 10.1039/C7BM01096F10.1039/C7BM01096F ↗
13. 10.1007/s12274-021-3624-410.1007/s12274-021-3624-4 ↗
14. 10.1002/anbr.20200005210.1002/anbr.202000052 ↗
15. 10.1016/j.bioactmat.2022.06.01310.1016/j.bioactmat.2022.06.013 ↗
16. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
17. 10.1016/j.jconrel.2022.03.04310.1016/j.jconrel.2022.03.043 ↗
18. 10.1016/j.jcis.2022.12.08810.1016/j.jcis.2022.12.088 ↗
19. 10.1016/j.jcis.2022.02.08310.1016/j.jcis.2022.02.083 ↗
20. 10.1021/acsnano.2c0296510.1021/acsnano.2c02965 ↗
21. 10.1021/acsami.2c1818410.1021/acsami.2c18184 ↗
22. 10.1002/smll.20230366810.1002/smll.202303668 ↗
23. 10.1021/acs.accounts.8b0019510.1021/acs.accounts.8b00195 ↗
24. 10.1021/nn100534q10.1021/nn100534q ↗
25. 10.1039/C8NH00417J10.1039/C8NH00417J ↗
26. 10.3390/ma1515529010.3390/ma15155290 ↗
27. 10.1021/ja312004m10.1021/ja312004m ↗
28. 10.1002/smll.20130192610.1002/smll.201301926 ↗
29. 10.1039/C5TB02548F10.1039/C5TB02548F ↗
30. 10.1016/j.ijbiomac.2021.06.00410.1016/j.ijbiomac.2021.06.004 ↗
31. 10.1016/j.jconrel.2018.03.01210.1016/j.jconrel.2018.03.012 ↗
32. 10.1016/j.nantod.2019.10080010.1016/j.nantod.2019.100800 ↗
33. 10.1016/j.biomaterials.2020.12064710.1016/j.biomaterials.2020.120647 ↗
34. 10.1007/s12274-023-5833-510.1007/s12274-023-5833-5 ↗
35. 10.1002/adma.20170117010.1002/adma.201701170 ↗
36. 10.1038/s41467-023-40474-910.1038/s41467-023-40474-9 ↗
37. 10.1002/anie.20150828810.1002/anie.201508288 ↗
38. 10.1038/natrevmats.2016.7510.1038/natrevmats.2016.75 ↗
39. Kuppusamy P. · Cancer Res. · 2002 · 62 · 307
40. 10.1016/j.jconrel.2021.10.02810.1016/j.jconrel.2021.10.028 ↗
41. 10.1016/j.biomaterials.2016.10.05210.1016/j.biomaterials.2016.10.052 ↗
42. 10.1016/j.pharmthera.2016.03.01310.1016/j.pharmthera.2016.03.013 ↗